Sep 25, 2026 · 5 min
AI momentum lifts Meta as Gen Digital stumbles
Weekly Roundup: Meta's AI-Driven Rally, Gen Digital Drops, Moderna Surges
The episode shows how product traction, takeover speculation, and clinical data can rapidly reshape investor sentiment across technology, cybersecurity, and biotech.
- 1Meta’s shares rallied as Muse gained traction and the company announced a dedicated AI device.
- 2Gen Digital fell sharply after reports that it was considering an acquisition of GoDaddy.
- 3Moderna surged on additional data for a personalized cancer vaccine developed with Merck.
Don't miss
Moderna’s surge is linked to additional data for a personalized cancer vaccine whose potential may extend beyond melanoma.
The brief
Meta led the week’s upside after Muse became the top free app on Apple’s App Store, adding evidence that its AI push is reaching consumers.
Hosts Tim Stenovec and Carol Massar speak with equities reporter Avalon Purnell about Meta’s rally and the company’s dedicated AI device announcement.
Gen Digital moved in the opposite direction: its shares dropped 25% for the week after reports of early talks to acquire GoDaddy.
Moderna shares surged after the company confirmed additional data for its personalized cancer vaccine, developed with Merck and currently focused on melanoma.
The broader question is whether Moderna’s vaccine can extend beyond melanoma, turning a focused clinical story into a potentially wider treatment opportunity.
What was said on this episode
4 statements · 3 positive · 1 neutral
Meta's Muse is helping push Meta's shares toward a $2 trillion valuation
“the tool is really helping to push the shares even close to the $2 trillion mark”
Listen at 1:09
Meta is potentially on track for its best monthly performance since 2013
“It's actually on track potentially to have its best month since 2013”
Listen at 1:56
Gen Digital is reportedly considering an early-stage takeover of GoDaddy
“they are considering potentially in an early talks to take over GoDaddy”
Listen at 2:25
Moderna's cancer vaccine could address other markets with higher total addressable markets
“that it could actually hit other areas that maybe could have a higher TAM”
Listen at 3:24
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
Apple Inc.
Mark Elliot ZuckerbergListen to the full episode and explore every guest, topic, and moment on PodLume.